Buprenorphine is a partial opioid agonist with FDA-approved indications for pain management and opioid use disorder. Use of buprenorphine for chronic pain, opioid use disorder, or both, has increased substantially over the past several years. This presentation will review initial dosing of buprenorphine products FDA-approved for pain management, highlight information about off-label use of buprenorphine for pain management, and discuss appropriate monitoring when transitioning to or from buprenorphine products.
Wednesday, April 5, 2023
3:00pm ET
Amanda Lovell, PharmD, BCGP; Optum
1. Register for the Live Webcast: To attend the live session, please register here in advance.
Each person attending must register online using his/her email address. Once registered, you will receive a confirmation email which includes instructions and link.
Please contact ohs-llinfo@optum.com with any questions.
**NOTE: LeadingAge Ohio members use code LAO in the Group ID field when registering for this event.**